Q2 FY2026 · ended Jun 30, 2026 · Revenue $36,400, +142.7% YoY · Filed Aug 12, 2026
Vivos Inc. (RDGL) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $36,400 and a net loss of $830,189. Free cash flow was -$834,119. As of Jun 30, 2026 it held $2.3 million in cash and investments and $103,153 in total debt.
Revenue
$36,400
+142.7% vs year-ago quarter
Net income
$-830,189
-28.6% vs year-ago quarter
Operating cash flow
$-739,580
-22.3% vs year-ago quarter
Free cash flow
$-834,119
-43.5% vs prior quarter
EPS
$0.00
Dividend per share
None
Shares outstanding
494.21M
+8.9% vs year-ago quarter
Net cash
$2.23M
Q2 FY2026
Operating margin
-2852.5%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- RDGL (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Richland, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1449349
- Former names
- ADVANCED MEDICAL ISOTOPE Corp (until Dec 18, 2017)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $36,400 | $36,068 | $24,752 | $1,879 | $15,000 |
| Operating income | -$654,529 | -$545,492 | -$1.1M | -$531,023 | -$674,773 |
| Net income | -$830,189 | -$1.2M | -$1.1M | -$507,294 | -$645,513 |
| Diluted EPS | $0.00 | $0.00 | -$0.00 | $0.00 | $0.00 |
| Operating cash flow | -$739,580 | -$429,861 | -$539,554 | -$458,481 | -$604,510 |
| Free cash flow | -$834,119 | -$581,066 | — | — | — |
| Total assets | $2.9M | $3.0M | $1.9M | $2.3M | $2.8M |
| Total liabilities | $123,955 | $253,195 | $206,743 | $112,693 | $96,458 |
| Stockholders' equity | $2.8M | $2.7M | $1.7M | $2.2M | $2.7M |
| Cash and investments | $2.3M | $2.5M | $1.6M | $2.2M | $2.7M |
| Total debt | $103,153 | $109,593 | $114,271 | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights, Bylaw or fiscal year change
|
Oct 8, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 5, 2026 | Sep 28, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Nov 12, 2025 | Sep 30, 2025 |
All 496 Vivos Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.